Shandong Boan Biotechnology Co., Ltd. (06955.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 2.13B

MomentumView details →

1D Return

−2.42%

YTD Return

−59.71%

RSI (14)

20.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 2.13B

RSI (14)

20.1

MomentumView details →

1D Return

−2.42%

YTD Return

−59.71%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−HKD 0.02

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Boan Biotech announced that its investigational drug BA2201, a long-acting bispecific antibody targeting TL1A and IL-23 for inflammatory bowel disease, has had its new drug clinical trial application accepted for review by the Center for Drug Evaluation of China's National Medical Products Administration.10d ago

Boan Biotech issued a profit warning, expecting a net loss of RMB 79 million to 89 million for the six months ended June 2026, compared to a profit of RMB 21 million in the same period last year, due to increased R&D expenses from its accelerated innovation strategy.20d ago

Similar companies

Aurinia Pharmaceuticals Inc.AUPH Zenas BioPharma, Inc.ZBIO ADMA Biologics, Inc.ADMA UroGen Pharma Ltd.URGN Zymeworks Inc.ZYME Rapport Therapeutics, Inc. Common StockRAPP Find similar companies →

Latest newsMore news →

Boan Biotech announced that its investigational drug BA2201, a long-acting bispecific antibody targeting TL1A and IL-23 for inflammatory bowel disease, has had its new drug clinical trial application accepted for review by the Center for Drug Evaluation of China's National Medical Products Administration.10d ago Boan Biotech issued a profit warning, expecting a net loss of RMB 79 million to 89 million for the six months ended June 2026, compared to a profit of RMB 21 million in the same period last year, due to increased R&D expenses from its accelerated innovation strategy.20d ago